Joseph Foss

Joseph Foss

Company: NeuroTherapia Inc

Job title: Chief Medical Officer

Seminars:

Using a Synthetic CB2-Targeting Compound to Target Neuroinflammation in the Brain, Mitigating Alzheimer’s Disease 2:00 pm

Keeping up with the evolving translational models of CB2-targeting compounds Understanding the pathways behind CB2-targeting to treat the neurological symptoms of AD through microglial-mediated neuroinflammation Preclinical and clinical research of a candidate compound, NTRX-07, that can readily penetrate the brain and modulate microglial activity via the CB2 receptor Exploring possible synergistic effects of NTRX-07 with…Read more

day: Day Two

A Hanson Wade Group Company

© Copyright 2024 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.